According to current evidence, the effect of EZH2-H3K27me3 pathway to platinum resistance was heterogeneous in different cancer types: EZH2/H3K27me3 contributed to platinum resistance in ovarian cancer, cervical cancer, colorectal cancer, lung cancer and gastric cancer while sensitizing osteosarcoma and lymphoma to platinum treatment. This evidence concerns the gene EZH2 and ovarian cancer.